Oligometastatic disease is an evolving space in metastatic cancer. More recently, there has been a push toward clearer definition of this entity and a trend towards considering local therapies directed at the oligometastatic sites of disease. This talk explores the current evidence in this disease state with respect to outcomes and toxicities with a particular focus on lung cancer.